# Evaluating the effectiveness of a population-level health intervention to increment HCV treatment coverage in tuscany region, Italy: An interrupted time series analysis

## TL;DR

This study evaluates how a health intervention in Tuscany, Italy, increased Hepatitis C treatment access using data from 2015 to 2022.

## Contribution

The study provides evidence on the effectiveness of a population-level intervention to boost HCV treatment coverage using an interrupted time series model.

## Key findings

- The health intervention significantly increased DAA treatment coverage in the general population.
- No significant effects were observed in specific sub-population groups.
- Findings support policies to boost HCV screening and simplify DAA access.

## Abstract

Worldwide, an estimated 57.8 million people are chronically infected with the Hepatitis C virus (HCV). The advent of direct-acting antivirals (DAAs) has made possible the definition of elimination targets by 2030. This study aimed to evaluate the effectiveness of a population-level health intervention to expand access to HCV treatment in the Tuscany Region, Italy. We used individual-level administrative data from the Tuscany region, collected between January 2015 and December 2022. Data include monthly observations on i) the number of serological tests to detect HCV, ii) the number of PCR tests to detect HCV and, iii) the number of prescriptions of direct-acting antivirals against HCV. We implemented an Interrupted Time Series (ITS) model, where the primary outcome was the number of monthly prescriptions of direct-acting antivirals, while the number of tests to detect HCV were included as control variables. The analysis was implemented i) in the general population, ii) in specific sub-population groups. Results show that the health intervention promoted by the Tuscany Regional Health Authority was highly effective in increasing DAAs treatment coverage in the general population, while no significant effects were observed among sub-population groups. Findings of this study provide evidence to support policies at national and subnational levels to booster HCV screening and simplify access to DAA prescriptions.